Aardvark Therapeutics, Inc.

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, in the United States. According to its official website, the company is focused on "rethinking metabolic health" and describes itself as developing novel, small-molecule therapies designed to inhibit hunger and treat metabolic diseases. Its stated scientific premise is that hunger and appetite are distinct neurologic drives: appetite reflects desire for reward or pleasure, whereas hunger is driven by the need to avoid pain and discomfort. Aardvark positions itself around alleviating hunger specifically, rather than appetite or reward-driven eating, as the basis for treating metabolic disease. The company's lead asset is ARD-101, described on its website as an oral investigational drug being developed for the treatment of hunger-associated rare diseases. ARD-101 is said to be primarily limited to the digestive tract, where it activates bitter taste receptors (TAS2Rs) to trigger local release of satiety hormones, activating gut-brain signals that suppress hunger. This mechanism places the company in the broader metabolic and obesity drug space, but with a differentiated, peripherally restricted oral small-molecule approach. Aardvark states that its goal is to become a leader in the treatment of hunger, with potential applications in hyperphagia in rare diseases as well as obesity and obesity-related conditions. Its website specifically highlights Prader-Willi syndrome and general obesity as areas of interest. As a clinical-stage company, its programs are investigational and have not been established as safe or effective by regulators. The company maintains a public web presence at aardvarktherapeutics.com and lists Instagram, Facebook, and LinkedIn as its social channels. Public reference data identifies it as a company located in San Diego, United States.

Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company located in San Diego, California, United States. Public reference data identifies it as a company in San Diego. The company's own website presents its mission as "rethinking metabolic health" and describes it as developing novel, small-molecule therapies designed to inhibit hunger and treat metabolic diseases. The company's scientific approach rests on a distinction between hunger and appetite. According to its website, hunger and appetite are distinct neurologic drives that influence a person's behavior toward food consumption: appetite reflects desire for reward or pleasure, whereas hunger is driven by the need to avoid pain and discomfort. Although these perceptions interact neurologically, Aardvark states that they remain unique and distinguishable processes. The company says it is focused on alleviating hunger to treat metabolic diseases and to deliver transformative outcomes for patients. Aardvark's lead compound is ARD-101, described as an oral investigational drug being developed for the treatment of hunger-associated rare diseases. The company states that ARD-101 is primarily limited to the digestive tract, where it activates bitter taste receptors (TAS2Rs) to trigger the local release of satiety hormones, which in turn activate gut-brain signals that suppress hunger. This mechanism is intended to address hunger-driven conditions while remaining peripherally restricted to the digestive tract. The company states that its goal is to become a leader in the treatment of hunger, which it sees as having potential applications in the treatment of hyperphagia in rare diseases as well as obesity and obesity-related conditions. Its website specifically names Prader-Willi syndrome and general obesity as areas of interest. As a clinical-stage company, Aardvark's programs remain investigational; no product has been approved by regulators based on the information provided. The company maintains a public web presence at aardvarktherapeutics.com and lists Instagram, Facebook, and LinkedIn as its social media channels. Its website footer carries a copyright notice dated 2026.

Clinical-stage biopharmaceutical company focused on inhibiting hunger to treat metabolic diseases, with a lead oral small-molecule candidate targeting bitter taste receptors in the gut.

• ARD-101

  Oral investigational small-molecule drug candidate being developed for the treatment of hunger-associated rare diseases. It is described as primarily limited to the digestive tract, where it activates bitter taste receptors (TAS2Rs) to trigger local release of satiety hormones and activate gut-brain signals that suppress hunger.

1. 1Home - Aardvark Therapeuticsaardvarktherapeutics.com
2. 2Aardvark Therapeutics, Inc. (United States) - Wikidatawikidata.org